Acasă › Cancer endometrial › New York › New York City
Studii clinice pentru Cancer endometrial în New York City, NY
52 studii pentru Cancer endometrial caută participanți în și în jurul orașului New York City (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
În curs de recrutareFaza 3
- Mount Sinai Chelsea, New York
- Mount Sinai West, New York
- Mount Sinai Hospital, New York
- și încă 3
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
În curs de recrutareFaza 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of PHST001 in Advanced Solid Tumors
În curs de recrutareFaza 1
- Mount Sinai, New York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
În curs de recrutareFaza 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 2
- Memorial Sloan Kettering Hospital, New York
Study of AVZO-021 in Patients With Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Avenzo Therapeutics Recruiting Site, New York
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
În curs de recrutareFaza 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
În curs de recrutare
- Memorial Sloan Kettering Cancer Center, New York
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
În curs de recrutareFaza 1
- Research Site, New York
- Research Site, New York
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
În curs de recrutareFaza 2
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
În curs de recrutareFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
În curs de recrutareFaza 1
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
În curs de recrutareFaza 1/2
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
În curs de recrutareFaza 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
În curs de recrutareFaza 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
În curs de recrutareFaza 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
În curs de recrutareFaza 3
- NYU Langone Health, New York
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
În curs de recrutareFaza 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6004), New York
- Memorial Sloan Kettering Cancer Center ( Site 6053), New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
În curs de recrutareFaza 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
În curs de recrutareFaza 3
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street, New York
- Perlmutter CC NYU Langone LI, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
În curs de recrutareFaza 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
În curs de recrutareFaza 1
- Memorial Sloan Kettering Cancer Center, New York
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
În curs de recrutareFaza 3
- Research Site, New York
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
În curs de recrutareFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
În curs de recrutareFaza 1
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
În curs de recrutareFaza 1
- Icahn School of Medicine at Mount Sinai, New York
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
În curs de recrutareFaza 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
În curs de recrutareFaza 2
- Laura & Isaac Perlmutter Cancer Center, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Mount Sinai Health System, New York
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
În curs de recrutareFaza 1
- Memorial Sloan Kettering Cancer Center, New York
FOG-001 in Locally Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
În curs de recrutareStudiu observațional
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
În curs de recrutareFaza 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- NYP/Weill Cornell Medicine, New York
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
În curs de recrutareFaza 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
În curs de recrutareFaza 2
- Memorial Sloan Kettering Cancer Center, New York
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
În curs de recrutareFaza 2
- Memorial Sloan Kettering Cancer Center, New York
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
În curs de recrutareFaza 1/2
- New York University Langone Health, New York
- ICHAN School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
În curs de recrutareFaza 1 timpurie
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4175408 in Participants With Advanced Cancer
În curs de recrutareFaza 1
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
În curs de recrutareFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
În curs de recrutareFaza 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of a Weight Loss Intervention in People With Endometrial Cancer
În curs de recrutareFaza 1 timpurie
- Memorial Sloan Kettering Cancer Center, New York
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
În curs de recrutareFaza 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
În curs de recrutareFaza 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer
În curs de recrutare
- Memorial Sloan Kettering Cancer Center, New York
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
În curs de recrutareFaza 2
- Memorial Sloan Kettering Cancer Center, New York
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
În curs de recrutareFaza 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
În curs de recrutareFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
În curs de recrutareStudiu observațional
- Massive Bio SYNERGY-AI site, New York
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
În curs de recrutareFaza 1/2
- NYU Langone Health, New York
Comprehensive Outcomes for After Cancer Health
În curs de recrutareVoluntari sănătoși bineveniți
- Memorial Sloan Kettering Cancer Center, New York
Studii pentru Cancer endometrial în alte orașe
- Houston, TX68 studii
- Boston, MA50 studii
- Arlington, VA39 studii
- Nashville, TN38 studii
- Los Angeles, CA34 studii
- St. Louis, MO29 studii
- Philadelphia, PA28 studii
- San Antonio, TX27 studii
- Columbus, OH25 studii
- Oklahoma City, OK25 studii
- Chicago, IL25 studii
- Queens, NY25 studii
Alte studii în New York City
- Cancer de sân136 studii
- Cancer pulmonar cu celule non-pătrate121 studii
- Cancer (toate tipurile)109 studii
- Cancer de prostată103 studii
- Cancer metastatic93 studii
- Cancer colorectal78 studii
- Cancer ovarian69 studii
- Cancer pulmonar60 studii
- Mielom multiplu60 studii
- Cancer pancreatic60 studii
- Leucemie mieloasă acută51 studii
- Insuficiență cardiacă51 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.